Applied Therapeutics (NASDAQ:APLT) Releases Earnings Results, Misses Expectations By $0.05 EPS

Applied Therapeutics (NASDAQ:APLTGet Rating) issued its earnings results on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.05), MarketWatch Earnings reports.

Applied Therapeutics stock opened at $1.72 on Friday. Applied Therapeutics has a twelve month low of $1.45 and a twelve month high of $25.59. The company’s 50-day moving average price is $2.00 and its two-hundred day moving average price is $5.44.

In other Applied Therapeutics news, insider Riccardo Perfetti bought 30,000 shares of the stock in a transaction dated Wednesday, March 23rd. The shares were bought at an average cost of $1.97 per share, with a total value of $59,100.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 27.20% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Applied Therapeutics by 5.0% during the first quarter. BlackRock Inc. now owns 1,363,403 shares of the company’s stock worth $2,876,000 after purchasing an additional 64,872 shares during the period. State Street Corp increased its holdings in shares of Applied Therapeutics by 8.8% during the fourth quarter. State Street Corp now owns 341,651 shares of the company’s stock worth $3,058,000 after purchasing an additional 27,700 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Applied Therapeutics by 1,503.4% during the first quarter. Renaissance Technologies LLC now owns 282,200 shares of the company’s stock worth $595,000 after purchasing an additional 264,600 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Applied Therapeutics by 21.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 75,505 shares of the company’s stock worth $676,000 after acquiring an additional 13,415 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Applied Therapeutics by 45.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 72,925 shares of the company’s stock worth $653,000 after acquiring an additional 22,741 shares in the last quarter. 95.51% of the stock is currently owned by institutional investors.

A number of brokerages have recently issued reports on APLT. Truist Financial dropped their target price on shares of Applied Therapeutics to $6.00 in a report on Wednesday, April 13th. Barclays lowered their price target on shares of Applied Therapeutics from $7.00 to $2.50 and set an “equal weight” rating on the stock in a report on Monday, March 21st. Finally, Zacks Investment Research raised shares of Applied Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Wednesday, March 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Applied Therapeutics has a consensus rating of “Hold” and a consensus target price of $12.08.

Applied Therapeutics Company Profile (Get Rating)

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.

Featured Articles

Earnings History for Applied Therapeutics (NASDAQ:APLT)

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.